Commentary

Video

Part 7: Ask the Experts: What problem in ophthalmology do you wish there was a solution for?

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

Vikas Chopra, MD:

Yeah. I mean, if we can cure blindness, that would be amazing. So, you know, we are, of course, moving in that direction with, you know, stem cell treatments, perhaps regeneration of the optic nerve. There's already stem cell trials for retina, which is quite promising. So I think if we can, you know, really–that's one thing, if we can achieve that, would be amazing. The second thing is, of course, which we made a lot of strides in, is early detection. If you can detect disease states, earlier intervention is just much less invasive, and you have a better chance of preservation and vision. This is especially critical now, as we're all living longer. I mean, it's not infrequent that I have every clinic session, maybe one or two patients who are over the age of 90, and often over the age of 93 in my clinic. And so we have to understand that people are living longer. We have to preserve their vision for longer. So the earlier you can find disease, treat it appropriately, in a responsible manner. You can, you know, improve their quality of life.

John D Sheppard, MD, MMSc, FACS

I think a broader perspective is cure. As ophthalmologists, we cure cataracts. That's really exciting, but there's not a whole lot of other things that we cure. We prevent, we maintain, we manage, we reverse conditions. So where will the cures be? The cures will be with understanding genetics, the true etiology of so many conditions. And we know that, for instance, we have a number of relevant genetic markers for diseases like age related macular degeneration, glaucoma, Fuchs' dystrophy and so many retinal dystrophies that are with decades blinding. And there are genetic treatments, genetic analyzes for just about every disease that we deal with. I think the next revolution in ophthalmology will truly be curing conditions to which we as humans are genetically predisposed. And this is the thrust of so many new startup companies being partnered and then acquired by strategics. They're expensive now because the understanding, the technology, the clinical trials are so costly and so new, it's a whole novel field. I think the next generation of ophthalmologists will have cures for so many of the diseases that they see.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.